

Tiffany Troso-Sandoval, MD

Medical Oncologist | Breast & Gynecologic Cancers | Expert Witness

Email: legal@drtiffanytroso.com | Phone: 917-647-1718 Location: Long Island, NY

Professional Summary

Double board-certified medical oncologist with over 25 years of clinical experience specializing in breast and gynecological cancers. Former senior attending physician at Memorial Sloan Kettering Cancer Center in New York. Currently providing expert witness services for legal cases involving oncology-related matters. Recognized for clinical expertise, clear communication, and evidence-based analysis in both medical and legal contexts.

Expert Witness Experience

Expert Medical Consultant and Witness

Self-employed | 2022–Present

- Provide expert medical opinions, written reports, and testimony in legal cases involving oncology.
- Areas of expertise: standard of care, delayed diagnosis, and causation in breast and gynecologic cancer.
- Experienced in depositions, trial testimony, and chart review.
- Retained by multiple law firms across NY, NJ, CT, PA, MD and FL.

Educational Background

- **BA in Molecular Biology**

Princeton University, Princeton, NJ — 1987–1991

- **Medical Doctor (MD)**

Weill Medical College of Cornell University, New York, NY — 1992–1996

Post-Doctoral Training

- **Internship, Internal Medicine**
New York Hospital/Cornell University — 1996–1997
- **Residency, Internal Medicine**
New York Hospital/Cornell University — 1997–1999
- **Fellowship, Medical Oncology**
Memorial Sloan-Kettering Cancer Center — 1999–2001

Licensure and Certification

- **Medical Licenses:**
 - New York (208384)
 - New Jersey (25MA1098800)
 - Florida (telehealth) (TPME3717)
- **DEA Number:** BT7378347
- **NPI Number:** 15583411982

Board Certification

- ABIM: Internal Medicine (1996–2019)
- ABIM: Medical Oncology (2001–present)

Professional Clinical Experience

- **Assistant Attending Physician**
Memorial Hospital for Cancer & Allied Diseases, Rockville Centre, NY — 2001–2013
- **Associate Attending Physician**
Memorial Hospital for Cancer & Allied Diseases, Rockville Centre, NY — 2013–2019
- **Department of Gynecologic Medical Oncology**
MSKCC at Nassau, Uniondale, NY — 2019–2024

Other Work Experience

- **CEO/Founder, Winning The Cancer Journey, LLC**
Provides education, support, and guidance to female oncology patients through online courses, coaching, and group support.

- **Chief Medical Officer, Second Look Oncology, PLLC**
 - **Expert medical witness work in breast and gynecological cancer cases.**
 - Offers virtual second opinions and oncology consults for patients with breast and gynecologic cancer.
- **Consultant & Advisor Roles:**
 - Hologic/Biotheranostics – Expert Speaker, The Breast Cancer Index (2020–present)
 - Immunogen/AbbVie – Advisory Board Member (2022–present)
- **Media and Education:**
 - Editorial Advisor, Women's Health
 - Medical Consultant, CNN
 - Keynote Speaker

Teaching and Mentorship

- Co-Regional Director, COOL Scholars Program, MSKCC — 2016–2024
- Clinical Teaching for RNs and NPs, MSKCC Nassau — 2019–2024
- Oncology Lectures, Catholic Health Nurses and Staff — 2007–2024

Professional Memberships

- American Society of Clinical Oncology (ASCO) — Member since 2001
- Society of Gynecologic Oncologists — Member since 2015
- Society for Integrative Oncology — Member since 2016
- Institute for Functional Medicine — Member since 2024

Honors and Awards

- "Doctor of Distinction in Oncology" — Long Island PULSE Magazine, May 2016
- "Top 15 Breast Cancer Providers, The A List" — Long Island Press, Fall 2023

Publications

Articles in Professional Peer-Reviewed Journals

1. Friedman CF, Manning-Geist BL, Zhou Q, Soumerai T, Holland A, Da Cruz Paula A, Green H, Ozsoy MA, Iasonos A, Hollmann T, Leitao MM Jr, Mueller JJ, Makker V, Tew WP, O'Cearbhaill RE, Liu YL, Rubinstein MM, **Troso-Sandoval T**, Lichtman SM, Schram A, Kyi C, Grisham RN, Causa Andrieu P, Wherry EJ, Aghajanian C, Weigelt B, Hensley ML, Zamarin D. **"Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses."** *Nature Medicine*. 2024 May;30(5):1330-1338.
2. Lumish M, Chui MH, Zhou Q, Iasonos A, Sarasohn D, Cohen S, Friedman C, Grisham R, Konner J, Kyi C, Rubinstein M, **Troso-Sandoval T**, Aghajanian C, Makker V. **"A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma."** *Gynecol Oncol*. 2024.
3. Shen S, Ma W, Brown D, Da Cruz Paula A, Zhou Q, Iasonos A, Tessier-Cloutier B, Ross DS, **Troso-Sandoval T**, Reis-Filho JS, Abu-Rustum N, Zhang Y, Ellenson LH, Weigelt B, Makker V, Chui MH. **"HER2 genetic intratumor heterogeneity is associated with resistance to trastuzumab and trastuzumab emtansine therapy in recurrent high-grade endometrial cancer."** *Mod Pathol*. 2023.
4. Praiss AM, Zhou Q, Iasonos A, Moukarzel L, Dessources K, Soldan K, Su K, Sonoda Y, Roche KL, Gardner GJ, **Troso-Sandoval T**, Tew WP, Grisham RN, Chi DS, O'Cearbhaill RE, Zivanovic O. **"Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer."** *Gynecol Oncol*. 2023.
5. Rubinstein MM, Doria ER, Konner J, Lichtman S, Zhou Q, Iasonos A, Sarasohn D, **Troso-Sandoval T**, Friedman C, O'Cearbhaill R, Cadoo K, Kyi C, Cohen S, Soldan K, Billinson E, Caird I, Jang D, Eid K, Shah P, Guillen J, Aghajanian C, Zamarin D, Makker V. **"Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma."** *Gynecol Oncol*. 2023.
6. Walsh EM, Gucalp A, Patil S, Edelweiss M, Ross DS, Razavi P, Modi S, Iyengar NM, Sanford R, **Troso-Sandoval T**, Gorsky M, Bromberg J, Drullinsky P, Lake D, Wong S, DeFusco PA, Lamparella N, Gupta R, Tabassum T, Boyle LA, Arumov A, Traina TA. **"Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study."** *Breast Cancer Res Treat*. 2022.
7. Moore KN, Chambers SK, Hamilton EP, Chen LM, Oza AM, Ghamande SA, Konecny GE, Plaxe SC, Spitz DL, Geenen JJJ, **Troso-Sandoval TA**, Cragun JM, Rodrigo Imedio E, Kumar S, Mugundu GM, Lai Z, Chmielecki J, Jones SF, Spigel DR, Cadoo KA. **"Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer."** *Clin Cancer Res*. 2022.

8. Zivanovic O, Chi DS, Zhou Q, Iasonos A, Konner JA, Makker V, Grisham RN, Brown AK, Nerenstone S, Diaz JP, Schroeder ED, Langstraat CL, Paroder V, Lakhman Y, Soldan K, Su K, Gardner GJ, Andikyan V, Guo J, Jewell EL, Long Roche K, **Troso-Sandoval T**, Lichtman SM, Moukarzel LA, Dessources K, Abu-Rustum NR, Aghajanian C, Tew WP, Beumer J, Sonoda Y, O'Cearbhaill RE. **"Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer."** *J Clin Oncol.* 2021.
9. Tolaney SM, Wardley AM, Zambelli S, Hilton JF, **Troso-Sandoval TA**, Ricci F, Im SA, Kim SB, Johnston SRD, Chan A, Goel S, Catron K, Chapman SC, Price GL, Yang Z, Gainford MC, André F. **"Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer."** *Lancet Oncol.* 2020.
10. Rubinstein MM, Hyman DM, Caird I, Won H, Soldan K, Seier K, Iasonos A, Tew WP, O'Cearbhaill RE, Grisham RN, Hensley ML, **Troso-Sandoval T**, Sabbatini P, Guillen J, Selcuklu SD, Zime I, Torrisi J, Aghajanian C, Makker V. **"Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway."** *Cancer.* 2020.
11. Iyengar NM, Smyth L, Lake D, Gucalp A, Singh JC, Traina TA, DeFusco P, Dickler MN, Fornier MN, Goldfarb SB, Jhaveri K, Modi S, **Troso-Sandoval T**, Patil S, Ulaner G, Jochelson M, Norton L, Hudis CA, Dang CT. **"Efficacy and Safety of Gemcitabine with Trastuzumab and Pertuzumab after Prior Pertuzumab-based Therapy in Patients with Human Epidermal Growth Factor Receptor-2 Positive Metastatic Breast Cancer."** *JAMA Network Open.* 2019.
12. Soumerai TE, Donoghue MTA, Bandlamudi C, Srinivasan P, Chang MT, Zamarin D, Cadoo KA, Grisham RN, O'Cearbhaill RE, Tew WP, Konner JA, Hensley ML, Makker V, Sabbatini P, Spriggs DR, **Troso-Sandoval TA**, Charen AS, Friedman C, Gorsky M, Schweber SJ, Middha S, Murali R, Chiang S, Park KJ, Soslow RA, Ladanyi M, Li BT, Mueller J, Weigelt B, Zehir A, Berger MF, Abu-Rustum NR, Aghajanian C, DeLair DF, Solit DB, Taylor BS, Hyman DM. **"Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer."** *Clin Cancer Res.* 2018.
13. Iyengar NM, Fornier MN, Sugarman S, Theodoulou M, **Troso-Sandoval TA**, D'Andrea G, Drullinsky P, Fasano J, Gajria D, Goldfarb SB, Comen EA, Lake D, Modi S, Traina TA, Chen M, Patil S, Baselga J, Norton L, Hudis CA, Dang CT. **"A Pilot Study of Dose-Dense Paclitaxel with Trastuzumab and Lapatinib for node-negative, HER-2 Overexpressed Breast Cancer."** *Clin Breast Cancer.* 2016.

14. Drullinsky P, **Troso-Sandoval T**, Seidman AD, Yuan J, Patel H, Patil S, Norton L, Hudis C. **"Dose Dense Adjuvant Cyclophosphamide, Methotrexate, Fluorouracil is feasible at 14 Day Intervals."** *Clin Breast Cancer*. 2010.
15. Dang C, D'Andrea G, Lake D, Sugarman S, Fornier M, Moynahan ME, Gilewski T, Hurria A, Mills N, **Troso-Sandoval T**, George R, Robson M, Dickler M, Smith K, Panageas KS, Norton L, Hudis CA. **"Prolonged dose dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible."** *Clin Breast Cancer*. 2008.
16. Sugarman S, Wasserheit C, Hodgeman E, Coglianese M, D'Alessandro A, Fornier M, **Troso-Sandoval T**, D'Andrea G, Drullinsky P, Lake D, George R, Mills N, Moynahan M, Smith J, Panageas K, Norton L, Hudis C. **"A pilot study of dose dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma."** *Breast Cancer Res Treat*. 2008.
17. Dang C, Fornier M, Sugarman S, **Troso-Sandoval T**, Lake D, D'Andrea G, Seidman A, Sklarin N, Dickler M, Currie V, Gilewski T, Moynahan ME, Drullinsky P, Robson M, Wasserheit-Leiblich C, Mills N, Steingart R, Panageas K, Norton L, Hudis C. **"The safety of dose dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer."** *J Clin Oncol*. 2008.
18. Deng G, Vickers A, Yeung S, D'Andrea GM, Xiao H, Heerdt AS, Sugarman S, **Troso-Sandoval T**, Seidman AD, Hudis CA, Cassileth B. **"Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer."** *J Clin Oncol*. 2007.
19. Munster P, **Troso-Sandoval T**, Rosen N, Rifkind R, Marks P, Richon V. **"The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Induces Differentiation of Human Breast Cancer Cells."** *Clin Cancer Res*. 2001.
20. Xie Q-W, Cho H, Calaycay J, Mumford R, Swiderek K, Lee T, Ding A, **Troso T**, Nathan C. **"Cloning and Characterization of Inducible Nitric Oxide Synthase from Mouse Macrophages."** *Science*. 1992.

Reviews

- **Troso-Sandoval TA**, Lichtman SM. **"Chemotherapy of Ovarian Cancer in Elderly Patients."** *Cancer Biol Med*. 2015.